Patents by Inventor Achim Doerner

Achim Doerner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIBODY-DRUG CONJUGATES TARGETING EGFR AND MUC1 AND USES THEREOF
    Publication number: 20230310629
    Abstract: Provided are immunoconjugates comprising bispecific anti-MUC 1/EGFR antibodies conjugated to hemiasterlin-based moieties via cleavable linkers, and pharmaceutical compositions thereof. Provided also are methods of treating cancer using such immunoconjugates and pharmaceutical compositions.
    Type: Application
    Filed: June 3, 2021
    Publication date: October 5, 2023
    Inventors: Christine Knuehl, Lars Toleikis, Christiane Amendt, Achim Doerner, Alice Yam, Xiaofan Li, Ryan Stafford, Robert Henningsen, Sihong Zhou
  • BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF
    Publication number: 20220111064
    Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 14, 2022
    Applicant: Merck Patent GmbH
    Inventors: Achim DOERNER, Lars Toleikis, Vanita D. Sood, Carolin Sellmann, Christine Knuehl
  • Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
    Patent number: 11235063
    Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Achim Doerner, Lars Toleikis, Vanita D. Sood, Carolin Sellmann, Christine Knuehl
  • ANTI-C-MET ANTIBODIES AND ANTIBODY DRUG CONJUGATES THEREOF FOR EFFICIENT TUMOR INHIBITION
    Publication number: 20190248907
    Abstract: The present invention provides antibodies and heterodimeric immunoglobulin molecules, which bind cMET with high affinity and can be used to target cMET expressing tumor cells. The present invention also discloses methods of generating anti-cMET antibody drug conjugates using the inventive antibodies or heterodimeric immunoglobulin molecules as disclosed herein.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 15, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Achim DOERNER, Lars TOLEIKIS, Birgit PIATER, Laura RHIEL, Christine KNUEHL, Carolin SELLMANN, Simon KRAH
  • BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF
    Publication number: 20180326085
    Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.
    Type: Application
    Filed: October 27, 2016
    Publication date: November 15, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Achim DOERNER, Lars TOLEIKIS, SOOD D. Vanita, Carolin SELLMANN, Christine KNUEHL
  • Bispecific aptamers mediating tumour cell lysis
    Patent number: 8969318
    Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: March 3, 2015
    Assignee: Merck Patent GmbH
    Inventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner
  • BISPECIFIC APTAMERS MEDIATING TUMOUR CELL LYSIS
    Publication number: 20140039042
    Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.
    Type: Application
    Filed: December 12, 2011
    Publication date: February 6, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner